Skip to main content
Erschienen in: International Journal of Colorectal Disease 6/2004

01.11.2004 | Original Article

Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients

verfasst von: Innocenzo Sammarco, Gabriele Capurso, Luigi Coppola, Antonio Paniccià Bonifazi, Sara Cassetta, Gianfranco Delle Fave, Alessandro Carrara, Giovanni Battista Grassi, Pellegrino Rossi, Claudio Sette, Raffaele Geremia

Erschienen in: International Journal of Colorectal Disease | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

The proto-oncogene c-KIT encodes a tyrosine kinase receptor essential during embryonic development and postnatal life. Although deregulated expression of c-KIT has been reported, its role in colorectal carcinoma remains controversial: some authors have described a correlation between c-KIT expression and colorectal cancer (CRC), while others have failed to detect the receptor in the majority of neoplasia examined. To address this question, we designed a prospective study to analyze the expression of c-KIT in normal and neoplastic colonic mucosa of the same patient.

Patients and methods

We analyzed the tissues of 20 patients undergoing surgical resection for colorectal carcinoma by reverse transcriptase-polymerase chain reaction, Western blot and immunohistochemistry, whose results were correlated with histopathological parameters.

Results

Most patients (90%) showed c-KIT expression in normal tissue both at RNA and protein level, while in neoplastic tissue it was observed in 30% of patients at RNA level and in 10% at protein level. By immunohistochemistry the localization of c-KIT protein in the normal colon was restricted to interstitial cells scattered in the stroma, whereas the non-neoplastic epithelium was always negative. The mucinous carcinomas were all c-KIT negative, whereas the only case in which c-KIT was displayed in the neoplastic epithelium was a G3 adenocarcinoma.

Conclusion

Most colorectal carcinomas do not express c-KIT. We suggest that c-KIT expression is rarely present in this neoplasia; thus, the use of receptor inhibitors should be conducted in selected sub-groups of colon carcinoma patients, subsequent to the clear demonstration of c-KIT overexpression in the neoplastic cells.
Literatur
1.
Zurück zum Zitat Verdecchia A, Micheli A, Colonna M, Moreno V, Izarzugaza MI, Paci E (2002) EUROPREVAL Working Group. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Ann Oncol 13:1128–1139CrossRefPubMed Verdecchia A, Micheli A, Colonna M, Moreno V, Izarzugaza MI, Paci E (2002) EUROPREVAL Working Group. A comparative analysis of cancer prevalence in cancer registry areas of France, Italy and Spain. Ann Oncol 13:1128–1139CrossRefPubMed
2.
Zurück zum Zitat D’Entremont TS, Sun Weijing (2003) Recent advances in colorectal cancer therapy. Cancer Biol Ther 2:6–13PubMed D’Entremont TS, Sun Weijing (2003) Recent advances in colorectal cancer therapy. Cancer Biol Ther 2:6–13PubMed
3.
Zurück zum Zitat Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Ther Targets 7:215–234CrossRefPubMed Traxler P (2003) Tyrosine kinases as targets in cancer therapy—successes and failures. Expert Opin Ther Targets 7:215–234CrossRefPubMed
4.
Zurück zum Zitat Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703CrossRefPubMed Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20:1692–1703CrossRefPubMed
5.
Zurück zum Zitat Besmer P, Manova K, Duttlinger R, et al (1993) The kit-ligand (steel factor) and its receptor c-KIT/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 125–137 Besmer P, Manova K, Duttlinger R, et al (1993) The kit-ligand (steel factor) and its receptor c-KIT/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl 125–137
6.
Zurück zum Zitat Hassan HT, Zander A (1996) Stem cell factor as survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 95:257–262PubMed Hassan HT, Zander A (1996) Stem cell factor as survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol 95:257–262PubMed
7.
Zurück zum Zitat Ricotti E, Fagioli F, Garelli, E, et al (1998) C-KIT is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91:2397–2405PubMed Ricotti E, Fagioli F, Garelli, E, et al (1998) C-KIT is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 91:2397–2405PubMed
8.
Zurück zum Zitat Huang S, Luca M, Gutman M, et al (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339–2347PubMed Huang S, Luca M, Gutman M, et al (1996) Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 13:2339–2347PubMed
9.
Zurück zum Zitat He J, deCastro CM, Vandenbark GR, Busciglio J, Gabuzda D (1997) Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. Proc Natl Acad Sci USA 94:3954–3959CrossRefPubMed He J, deCastro CM, Vandenbark GR, Busciglio J, Gabuzda D (1997) Astrocyte apoptosis induced by HIV-1 transactivation of the c-kit protooncogene. Proc Natl Acad Sci USA 94:3954–3959CrossRefPubMed
10.
Zurück zum Zitat Bellone G, Silvestri S, Artusio E, et al (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J Cell Physiol 172:1–11CrossRefPubMed Bellone G, Silvestri S, Artusio E, et al (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-β1. J Cell Physiol 172:1–11CrossRefPubMed
11.
Zurück zum Zitat Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A (1992) Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 52:6139–6143PubMed Natali PG, Nicotra MR, Sures I, Santoro E, Bigotti A, Ullrich A (1992) Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res 52:6139–6143PubMed
12.
Zurück zum Zitat Matsuda R, Takahashi T, Nakamura S, et al (1993) Expression of the c-kit protein in human solid tumours and in corresponding fetal and adult normal tissues. Am J Pathol 142:339–346PubMed Matsuda R, Takahashi T, Nakamura S, et al (1993) Expression of the c-kit protein in human solid tumours and in corresponding fetal and adult normal tissues. Am J Pathol 142:339–346PubMed
13.
Zurück zum Zitat Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D (2002) Immunohistochemical staining for c-kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer 2:119–122PubMed Reed J, Ouban A, Schickor FK, Muraca P, Yeatman T, Coppola D (2002) Immunohistochemical staining for c-kit (CD117) is a rare event in human colorectal carcinoma. Clin Colorectal Cancer 2:119–122PubMed
14.
Zurück zum Zitat Manley PW, Cowan-Jacob SW, Buchdunger E, et al (2002) Imatinib a selective tyrosine kinase inhibitor. Eur J Cancer 38: S19–S27CrossRef Manley PW, Cowan-Jacob SW, Buchdunger E, et al (2002) Imatinib a selective tyrosine kinase inhibitor. Eur J Cancer 38: S19–S27CrossRef
15.
Zurück zum Zitat Druker BJ, Sawyers CL, Kantarjian H, et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMed Druker BJ, Sawyers CL, Kantarjian H, et al (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042PubMed
16.
Zurück zum Zitat Dagher R, Cohen M, Williams G, et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038PubMed Dagher R, Cohen M, Williams G, et al (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038PubMed
17.
Zurück zum Zitat Esposito I, Kleeff J, Bischoff SC, et al (2002) The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 82:1481–1492PubMed Esposito I, Kleeff J, Bischoff SC, et al (2002) The stem cell factor-c-kit system and mast cells in human pancreatic cancer. Lab Invest 82:1481–1492PubMed
18.
Zurück zum Zitat Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469–1473PubMed Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469–1473PubMed
19.
Zurück zum Zitat Hibi K, Takahashi T, Sekido Y, et al (1991) Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 6:2291–2296PubMed Hibi K, Takahashi T, Sekido Y, et al (1991) Coexpression of the stem cell factor and the c-kit genes in small cell lung cancer. Oncogene 6:2291–2296PubMed
20.
Zurück zum Zitat Timeus F, Crescenzio N, Valle P, et al (1997) Stem cell factor suppress apoptosis in neuroblastoma cell lines. Exp Hematol 25:1253–1260PubMed Timeus F, Crescenzio N, Valle P, et al (1997) Stem cell factor suppress apoptosis in neuroblastoma cell lines. Exp Hematol 25:1253–1260PubMed
21.
Zurück zum Zitat Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A (1992) Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 52:713–717PubMed Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A (1992) Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer 52:713–717PubMed
22.
Zurück zum Zitat Natali PG, Berlingieri MT, Nicotra MR, et al (1995) Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 55:1787–1791PubMed Natali PG, Berlingieri MT, Nicotra MR, et al (1995) Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 55:1787–1791PubMed
23.
Zurück zum Zitat Tonary AM, McDonald EA, Faugh W, Senterman MK, Vanderhyden BC (2000) Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int J Cancer 89:242–250CrossRefPubMed Tonary AM, McDonald EA, Faugh W, Senterman MK, Vanderhyden BC (2000) Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int J Cancer 89:242–250CrossRefPubMed
24.
Zurück zum Zitat Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39:793–799CrossRefPubMed Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K (2003) Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39:793–799CrossRefPubMed
25.
Zurück zum Zitat Lyford GL, He C-L, Soffer E, et al, (2002) Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51:496–501CrossRefPubMed Lyford GL, He C-L, Soffer E, et al, (2002) Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51:496–501CrossRefPubMed
26.
Zurück zum Zitat Hornick JL, Fletcher CD, (2003) Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 119:325–327PubMed Hornick JL, Fletcher CD, (2003) Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 119:325–327PubMed
27.
Zurück zum Zitat Toyota M, Hinoda Y, Itoh F, Takaoka A, Imai K, Yachi A (1994) Complementary DNA cloning of truncated form of c-kit in human colon carcinoma cells. Cancer Res 54: 272–275PubMed Toyota M, Hinoda Y, Itoh F, Takaoka A, Imai K, Yachi A (1994) Complementary DNA cloning of truncated form of c-kit in human colon carcinoma cells. Cancer Res 54: 272–275PubMed
28.
Zurück zum Zitat Takaoka A, Toyota M, Hinoda Y, Itoh F, Mita H, Kakiuchi H, Adachi M, Imai K (1997) Expression and identification of aberrant c-kit transcripts in human cancer cells. Cancer Lett 115:257–261CrossRefPubMed Takaoka A, Toyota M, Hinoda Y, Itoh F, Mita H, Kakiuchi H, Adachi M, Imai K (1997) Expression and identification of aberrant c-kit transcripts in human cancer cells. Cancer Lett 115:257–261CrossRefPubMed
29.
Zurück zum Zitat Rossi P, Marziali G, Albanesi C, Charlesworth A, Geremia R, Sorrentino V (1992) A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids. Dev Biol 152:203–207PubMed Rossi P, Marziali G, Albanesi C, Charlesworth A, Geremia R, Sorrentino V (1992) A novel c-kit transcript, potentially encoding a truncated receptor, originates within a kit gene intron in mouse spermatids. Dev Biol 152:203–207PubMed
30.
Zurück zum Zitat Sette C, Paronetto MP, Barchi M, Bevilacqua A, Geremia R, Rossi P (2002) Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J 21:5386–5395CrossRefPubMed Sette C, Paronetto MP, Barchi M, Bevilacqua A, Geremia R, Rossi P (2002) Tr-kit-induced resumption of the cell cycle in mouse eggs requires activation of a Src-like kinase. EMBO J 21:5386–5395CrossRefPubMed
31.
Zurück zum Zitat Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190CrossRefPubMed Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ (1999) Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 21:187–190CrossRefPubMed
32.
Zurück zum Zitat Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE (2002) Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21:7797–7807CrossRefPubMed Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE (2002) Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21:7797–7807CrossRefPubMed
33.
Zurück zum Zitat Shawer L, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123CrossRefPubMed Shawer L, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117–123CrossRefPubMed
34.
Zurück zum Zitat Attoub S, Rivat C, Rodrigues S, et al (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62:4879–4883PubMed Attoub S, Rivat C, Rodrigues S, et al (2002) The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy. Cancer Res 62:4879–4883PubMed
Metadaten
Titel
Expression of the proto-oncogene c-KIT in normal and tumor tissues from colorectal carcinoma patients
verfasst von
Innocenzo Sammarco
Gabriele Capurso
Luigi Coppola
Antonio Paniccià Bonifazi
Sara Cassetta
Gianfranco Delle Fave
Alessandro Carrara
Giovanni Battista Grassi
Pellegrino Rossi
Claudio Sette
Raffaele Geremia
Publikationsdatum
01.11.2004
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 6/2004
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-004-0601-9

Weitere Artikel der Ausgabe 6/2004

International Journal of Colorectal Disease 6/2004 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.